Next 10 |
home / stock / wve / wve articles
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday. Shares of Worthington Enterprises, Inc. (NYSE...
Wave Life Sciences Ltd (NASDAQ:WVE) announced results from its Phase 1b/2a SELECT-HD trial of WVE-003, which is being developed as a potential dise...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wa...
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unloc...
CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unloc...
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collab...
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unl...
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-q...
U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday. Shares of American Eagle Outfitters, Inc. (NYSE: AEO) ...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Wave Life Sciences Ltd. Website:
2024-07-17 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...